NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis $13.39 +0.25 (+1.90%) (As of 07/5/2024 ET) Add Compare Share Share Today's Range$12.83▼$13.4150-Day Range$11.43▼$15.1752-Week Range$8.08▼$20.98Volume110,108 shsAverage Volume202,120 shsMarket Capitalization$283.60 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Enanta Pharmaceuticals alerts: Email Address Enanta Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside41.9% Upside$19.00 Price TargetShort InterestBearish14.02% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment1.04Based on 2 Articles This WeekInsider TradingSelling Shares$89,590 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.95) to ($4.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.63 out of 5 starsMedical Sector225th out of 879 stocksPharmaceutical Preparations Industry97th out of 418 stocks 3.1 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Enanta Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.02% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEnanta Pharmaceuticals has received a 73.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Hepatitis medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Enanta Pharmaceuticals is -1.11. Previous Next 2.2 News and Social Media Coverage News SentimentEnanta Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $89,590.00 in company stock.Percentage Held by Insiders13.64% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enanta Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($5.95) to ($4.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Enanta Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on August 19.See his shocking evidence in this new report About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Read More ENTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTA Stock News HeadlinesJune 18, 2024 | insidertrades.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Sells $89,589.78 in StockJuly 4 at 1:34 AM | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Hold" by AnalystsJuly 7, 2024 | Stansberry Research (Ad)BUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).July 3, 2024 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Below Two Hundred Day Moving Average of $13.04May 29, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at the Jefferies Global Healthcare ConferenceMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed: Enanta Pharmaceuticals’ Clinical and Financial Prospects Bolster Investor ConfidenceMay 8, 2024 | finance.yahoo.comEnanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 8, 2024 | markets.businessinsider.comHold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial OutlookJuly 7, 2024 | Stansberry Research (Ad)BUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial ExecutionMay 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call TranscriptMay 7, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at the JMP Securities Life Sciences ConferenceMay 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ...May 7, 2024 | chron.comEnanta Pharmaceuticals: Fiscal Q2 Earnings SnapshotMay 6, 2024 | finance.yahoo.comEnanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst ExpectationsMay 6, 2024 | businesswire.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ETMay 5, 2024 | msn.comEnanta Pharma Q2 2024 Earnings PreviewMay 5, 2024 | markets.businessinsider.comEnanta Pharmaceuticals is about to announce its earnings — here's what to expectSee More Headlines Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/07/2024Next Earnings (Estimated)8/05/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees145Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$27.00 Low Stock Price Target$11.00 Potential Upside/Downside+41.9%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-133,820,000.00 Net Margins-180.76% Pretax Margin-178.25% Return on Equity-64.85% Return on Assets-29.28% Debt Debt-to-Equity RatioN/A Current Ratio6.43 Quick Ratio6.43 Sales & Book Value Annual Sales$79.20 million Price / Sales3.58 Cash FlowN/A Price / Cash FlowN/A Book Value$10.29 per share Price / Book1.30Miscellaneous Outstanding Shares21,180,000Free Float18,290,000Market Cap$283.60 million OptionableOptionable Beta0.60 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Jay R. Luly Ph.D. (Age 68)President, CEO & Director Comp: $1.25MMr. Paul J. Mellett Jr. (Age 69)Senior VP of Finance & Administration and CFO Comp: $666.84kDr. Yat Sun Or Ph.D. (Age 72)Senior VP of Research & Development and Chief Scientific Officer Comp: $729.31kMr. Nathaniel S. Gardiner J.D. (Age 70)Consultant Comp: $672.67kMr. Brendan Luu (Age 49)Senior Vice President of Business Development Comp: $622.86kMs. Jennifer VieraSenior Director of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsGenfitNASDAQ:GNFTXencorNASDAQ:XNCRProthenaNASDAQ:PRTAGyre TherapeuticsNASDAQ:GYRECollegium PharmaceuticalNASDAQ:COLLView All CompetitorsInsiders & InstitutionsTara Lynn KiefferSold 7,266 sharesTotal: $89,589.78 ($12.33/share)Farallon Capital Management LLCBought 70,000 shares on 5/24/2024Ownership: 9.891%Virtu Financial LLCBought 10,927 shares on 5/20/2024Ownership: 0.052%Jacobs Levy Equity Management Inc.Sold 366,291 shares on 5/16/2024Ownership: 0.919%California State Teachers Retirement SystemSold 1,255 shares on 5/16/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions ENTA Stock Analysis - Frequently Asked Questions How have ENTA shares performed this year? Enanta Pharmaceuticals' stock was trading at $9.41 on January 1st, 2024. Since then, ENTA stock has increased by 42.3% and is now trading at $13.39. View the best growth stocks for 2024 here. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) posted its quarterly earnings data on Monday, May, 6th. The biotechnology company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($1.26) by $0.21. The biotechnology company had revenue of $17.05 million for the quarter, compared to the consensus estimate of $16.47 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 64.85% and a negative net margin of 180.76%. What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA) and Netflix (NFLX). This page (NASDAQ:ENTA) was last updated on 7/7/2024 by MarketBeat.com Staff From Our PartnersWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTA Stock Alerts